NurExone Biologic Inc. (TSXV:NRX)
0.6800
+0.0300 (4.62%)
May 30, 2025, 4:00 PM EDT
NurExone Biologic Company Description
NurExone Biologic Inc., operates as a pharmaceutical technology company.
It is developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs.
The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications.
Its technology includes ExoPTEN, for acute spinal cord injury, and glaucoma; and Exosomes, nature’s guided missiles for regeneration and healing for specific tissues.
The company was founded in 2020 and is based in Toronto, Canada.
NurExone Biologic Inc.
Country | Canada |
Founded | 2020 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Lior Shaltiel |
Contact Details
Address: 1 Adelaide St. East Toronto, Ontario M5C 2V9 Canada | |
Website | nurexone.com |
Stock Details
Ticker Symbol | NRX |
Exchange | TSX Venture Exchange |
Fiscal Year | January - December |
Reporting Currency | USD |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jacob Licht | Chief Executive Officer of Exo-Top Inc. and Vice President of Corporate Development at NurExone |
Dr. Lior Shaltiel Ph.D. | Chief Executive Officer and Director |
Yoram Drucker | Co-Founder, Vice President of Strategic Development and Chairman |
Eran Ovadya M.B.A. | Chief Financial Officer, Financial Director and Secretary |
Gabriel Eldor | Co-Founder and Business Development Manager |
Dr. Shulamit Levenberg Ph.D. | Co-Founder and Member of Scientific Advisory Board |
Dr. Daniel Offen Ph.D. | Co-Founder |
Dr. Tali Kizhner | Director of Research and Development |
Prof. Nahshon Knoller M.D. | Head of the neurosurgery department at Shiba and Member of Scientific Advisory Board |
Dr. Ina Sarel Ph.D. | Head of CMC, Quality and Regulation |